Dual Antiplatelet Therapy in Acute Ischemic Stroke: A 2‐Time‐Window Study of CYP2C19 Genotypes and Functional Outcomes
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.126.049319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Yu-Hsuan Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Neurological Institute Taichung Veterans General Hospital Taichung Taiwan. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Ischemic Stroke, Clopidogrel, Platelet Aggregation Inhibitors. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Carriers of CYP2C19 loss‐of‐function alleles (LoFA) exhibit reduced metabolism of clopidogrel, potentially compromising the efficacy of dual antiplatelet therapy (DAPT) in acute ischemic stroke. We aimed to distinguish the impact of initial antiplatelet regimens from the discharge deescalation on functional outcomes.
Methods
The retrospective cohort study linked the prospective stroke registry with the Taiwan Precision Medicine Initiative biobank. Patients with mild to moderate acute ischemic stroke (National Institutes of Health Stroke Scale score ≤10) were included. Favorable outcomes (modified Rankin Scale score ≤1) of 2 windows were analyzed: (1) the acute window (≤48 hours), assessing outcomes at discharge, and (2) the deescalation window (discharge), assessing outcomes at 90 days.
Results
Among 741 patients, 463 (62.5%) were LoFA carriers. In the acute window, genotype was not associated with favorable outcomes; clinical severity (age, initial National Institutes of Health Stroke Scale score) was the dominant predictor. However, in the deescalation window, in the overall cohort, DAPT with aspirin and clopidogrel at discharge was independently associated with favorable outcomes at 90 days (odds ratio [OR], 2.34 [95% CI, 1.16–4.74]; P =0.018). Stratified analysis revealed that this benefit was driven primarily by LoFA carriers, in whom DAPT with aspirin and clopidogrel at discharge was independently associated with favorable outcomes (OR, 2.74 [95% CI, 1.17–6.38]; P =0.020). However, this association was attenuated in propensity score‐matched analyses, and there was no interaction between CYP2C19 LoFA carrier status and DAPT with aspirin and clopidogrel on favorable outcomes at 90 days.
Conclusions
CYP2C19 genotype did not predict early neurological deterioration. The potential long‐term clinical benefit of maintaining DAPT with aspirin and clopidogrel at discharge for LoFA carriers requires confirmation in adequately powered randomized trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Neurological Institute Taichung Veterans General Hospital Taichung Taiwan.
- Institute of Brain Science, School of Medicine National Yang Ming Chiao Tung University Taipei Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine National Chung Hsing University Taichung Taiwan.
ORCID-Profile: Chi-Sheng Wang, Kuo-Cheng Chang, Po-Lin Chen
Zitieren
APA
Wu, Y. H., Wang, C. S., Chang, K. C., & Chen, P. L. (2026). Dual Antiplatelet Therapy in Acute Ischemic Stroke: A 2‐Time‐Window Study of CYP2C19 Genotypes and Functional Outcomes. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.049319
Vancouver
Wu YH, Wang CS, Chang KC, Chen PL. Dual Antiplatelet Therapy in Acute Ischemic Stroke: A 2‐Time‐Window Study of CYP2C19 Genotypes and Functional Outcomes. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.049319
BibTeX
@article{Wu2026,
author = {Wu, Yu-Hsuan and Wang, Chi-Sheng and Chang, Kuo-Cheng and Chen, Po-Lin},
title = {Dual Antiplatelet Therapy in Acute Ischemic Stroke: A 2‐Time‐Window Study of CYP2C19 Genotypes and Functional Outcomes},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.126.049319}
}
EUVIMED